0001493152-24-020660.txt : 20240520
0001493152-24-020660.hdr.sgml : 20240520
20240520160014
ACCESSION NUMBER: 0001493152-24-020660
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240514
FILED AS OF DATE: 20240520
DATE AS OF CHANGE: 20240520
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lustig Marc
CENTRAL INDEX KEY: 0001940908
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40101
FILM NUMBER: 24964258
MAIL ADDRESS:
STREET 1: 4177 ROCKRIDGE ROAD
CITY: WEST VANCOUVER
STATE: A1
ZIP: V7W 1A3
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BriaCell Therapeutics Corp.
CENTRAL INDEX KEY: 0001610820
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 0731
BUSINESS ADDRESS:
STREET 1: 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR
CITY: WEST VANCOUVER
STATE: A1
ZIP: V7T 2X1
BUSINESS PHONE: (604) 921-1810
MAIL ADDRESS:
STREET 1: 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR
CITY: WEST VANCOUVER
STATE: A1
ZIP: V7T 2X1
FORMER COMPANY:
FORMER CONFORMED NAME: Ansell Capital Corp.
DATE OF NAME CHANGE: 20140613
4
1
ownership.xml
X0508
4
2024-05-14
0
0001610820
BriaCell Therapeutics Corp.
BCTX
0001940908
Lustig Marc
C/O BRIACELL THERAPEUTICS CORP.
235 15TH STREET,SUITE 300
WEST VANCOUVER
A1
V7T 2X1
BRITISH COLUMBIA, CANADA
1
0
1
0
0
Common Shares
2024-05-14
4
P
0
902935
2.215
A
2542935
I
By L5 Capital Inc.
Common Stock Warrants
2.11
2024-05-14
4
P
0
902935
A
Common Stock
902935
902935
I
By L5 Capital Inc.
The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer.
/s/ Marc Lustig
2024-05-20